Stock Events

Stock Events

Monumental Minerals 

0
88
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-6.26
-4.24
-2.22
-0.21
Expected EPS
-0.23225400000000002
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-13.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BE5.STU. It's not an investment recommendation.
Tesla
7
TSLA
NVIDIA
6
NVDA
AMD
6
AMD
Intel
6
INTC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc works on central nervous system (CNS) diseases, offering products that could be in direct competition with CNSP's pipeline.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. has a broad portfolio of treatments for neurological and neurodegenerative diseases, competing in the CNS space.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals focuses on the development and commercialization of medicines to treat central nervous system disorders, directly competing with CNSP.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a diverse biopharmaceutical portfolio, including treatments for neurological disorders, making it a competitor in the CNS market.
Novartis
NVS
Mkt Cap292.35B
Novartis AG offers a wide range of healthcare solutions, including treatments for CNS disorders, competing with CNSP's therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a significant presence in the development of drugs for neurological conditions, making it a competitor in the CNS pharmaceuticals market.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops therapies for various diseases, including CNS disorders, positioning it as a competitor to CNSP.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for CNS disorders, competing with CNSP in the broader healthcare market.

About

CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
Show more...
CEO
Rami Levin
Employees
8
Country
United States
ISIN
CA6153271037
WKN
000A41140

Listings

STU
DE
ZA6.STU
XNAS
US
CNSP
STU
DE
BE5.STU
F
DE
ZA6.F

0 Comments

Share your thoughts

FAQ

What is Monumental Minerals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Monumental Minerals stocks are traded under the ticker BE5.STU.
When is the next Monumental Minerals earnings date?▼
Monumental Minerals is going to release the next earnings report on November 18, 2026.
What were Monumental Minerals earnings last quarter?▼
BE5.STU earnings for the last quarter are -0.33 EUR per share, whereas the estimation was -0.21 EUR resulting in a -58.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Monumental Minerals revenue for the last year?▼
Monumental Minerals revenue for the last year amounts to 0 EUR.
What is Monumental Minerals net income for the last year?▼
BE5.STU net income for the last year is -13.81M EUR.
How many employees does Monumental Minerals have?▼
As of September 04, 2026, the company has 8 employees.
In which sector is Monumental Minerals located?▼
Monumental Minerals operates in the Health & Wellness sector.
When did Monumental Minerals complete a stock split?▼
Monumental Minerals has not had any recent stock splits.
Where is Monumental Minerals headquartered?▼
Monumental Minerals is headquartered in HOUSTON, United States.